Table 2.
Estimated values of CLact and F a F g in Caucasian and Asian populations (presented as the mean and 95% confidence intervals approximated with the Markov chain Monte Carlo method)
BCRP breast cancer resistance protein, CL act hepatic active uptake, CL pass passive diffusion, F a F g the product of the fraction of a dose absorbed and the fraction of a drug passing though the gut wall without metabolism
a F a F g,421CC is determined using ungenotyped Caucasian data based on the facts that the BCRP c.421AA frequency is very low in the Caucasian population, and that c.421CC and c.421CA carriers have similar pharmacokinetic profiles. Other parameters are determined by fitting genotyped data with F a F g,421CC fixed at its mean values
bIn estimating parameter values for pravastatin, CLpass is fixed at an assumed value to avoid huge uncertainty because of a correlation between CLact and CLpass. Details are given in the Electronic Supplementary Material